ORGANIC
LETTERS
2010
Vol. 12, No. 19
4416-4419
Enantioselective Total Synthesis of
Spirofungins A and B
Michael T. Crimmins* and Elizabeth A. O’Bryan
Kenan and Caudill Laboratories of Chemistry, UniVersity of North Carolina at Chapel Hill,
Chapel Hill, North Carolina 27599, United States
Received August 18, 2010
ABSTRACT
The enantioselective total synthesis of spirofungins A (1) and B (2) is reported in 14 steps over the longest linear sequence. Key steps include
the use of thiazolidinethione-mediated aldol reactions to assemble the major fragments and installation of the C1-C6 side chain using a
cross metathesis reaction.
Spirofungins A (1) and B (2) were isolated in 1998 as
secondary metabolites of Streptomyces Violaceusniger Tu¨
4113 as a 4:1 mixture.1 These spiroketal-containing natural
products differ only in the configuration about the C-15
spirocenter.2 The spirofungins, along with the structurally
related reveromycins,3 possess high antifungal activity
against yeasts, including the human pathogen Candida
albicans. Further biological studies by the Kozmin group
revealed that spirofungin A suppresses the growth of several
human cancer cell lines and selectively inhibits isoleucyl-
tRNA synthetase in vitro.4 The interesting structure and
biological profile of the spirofungins have resulted in two
total syntheses4,5 as well as several approaches to the
spiroketal core.6 Additionally, the Shimizu group has begun
investigating derivatives of both spirofungin A and the
reveromycins.7
Herein, we describe a highly convergent route to (-)-
spirofungin A (1) and (+)-spirofungin B (2) in which a cross
metathesis reaction would be employed to install the C1-C6
side chain 3 in an efficient manner (Scheme 1). The cross
metathesis partner, diene 4 or 5, was envisioned to arise from
the spiroketalization of ketone 6, available via a Horner-
Wadsworth-Emmons olefination, conjugate reduction se-
quence. The ꢀ-ketophosphonate 7, aldehyde 8, and ester 3
would be prepared using chiral auxiliary mediated aldol
reactions developed in our laboratories.8,9
Initial efforts were focused on the synthesis of aldehyde
8. Due to the required anti substitution, this fragment could
not be accessed directly from a thiazolidinethione-mediated
(1) Holtzel, A.; Kempter, C.; Metzger, J. W.; Jung, G.; Groth, I.; Fritz,
T.; Fiedler, H.-P. J. Antibiot. 1998, 51, 699–707.
(2) Zannatta, S. D.; White, J. M.; Rizzacasa, M. A. Org. Lett. 2004, 6,
1041–1044.
(6) (a) Shimizu, Y.; Kiyota, H.; Oritani, T. Tetrahedron Lett. 2000, 41,
3141–3144. (b) Shimizu, T.; Kusaka, J.; Ishiyama, H.; Nakata, T. Tetra-
hedron Lett. 2003, 44, 4965–4968. (c) Dias, L. C.; de Oliveira, L. G. Org.
Lett. 2004, 6, 2587–2590. (d) La Cruz, T. E.; Rychnovsky, S. D. Org. Lett.
2005, 7, 1873–1875.
(3) (a) Takahashi, H.; Osada, H.; Koshino, H.; Kudo, T.; Amano, S.;
Shimizu, S.; Yoshihama, M.; Isono, K. J. Antibiot. 1992, 45, 1409–1413.
(b) Takahashi, H.; Osada, H.; Koshino, H.; Sasaki, M.; Onose, R.;
Nakahoshi, M.; Yoshihama, M.; Isono, K. J. Antibiot. 1992, 45, 1414–
1419. (c) Koshino, H.; Takahashi, H.; Osada, H.; Isono, K. J. Antibiot.
1992, 45, 1420–1427.
(7) Shimizu, T.; Usui, T.; Fujikura, M.; Kawatani, M.; Satoh, T.;
Machida, K.; Kanoh, N.; Woo, J.-T.; Osada, H.; Sodeoka, M. Bioorg. Med.
Chem. Lett. 2008, 18, 3756–3760.
(4) Marjanovic, J.; Kozmin, S. A. Angew. Chem., Int. Ed. 2007, 46,
8854–8857.
(8) Crimmins, M. T.; King, B. W.; Tabet, E. A.; Chaudhary, K. J. J.
(5) Shimizu, T.; Satoh, T.; Murakoshi, K.; Sodeoka, M. Org. Lett. 2005,
Org. Chem. 2001, 66, 894–902
.
7, 5573–5576
.
(9) Crimmins, M. T.; Shamszad, M. Org. Lett. 2007, 9, 149–152.
10.1021/ol101961c 2010 American Chemical Society
Published on Web 09/10/2010